<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="due to secondary bacterial infections was observed for patients with" exact="pneumonia" post="(41 of 268). Most clinicians treated patients with SARS-CoV-2"/>
 <result pre="to 73.5% (n = 3,072) in all clinical reports of" exact="viral pneumonia" post="included in this review. For all cases of viral"/>
 <result pre="73.5% (n = 3,072) in all clinical reports of viral" exact="pneumonia" post="included in this review. For all cases of viral"/>
 <result pre="viral pneumonia included in this review. For all cases of" exact="viral pneumonia," post="a mortality rate of 10.9% due to secondary infections"/>
 <result pre="Staphylococcus aureus and Klebsiella pneumoniae. secondary bacterial infection pulmonary viruses" exact="viral pneumonia" post="SARS-CoV-2 COVID-19 influenza SARS antibiotic resistance fig-count: table-count: equation-count:"/>
 <result pre="aureus and Klebsiella pneumoniae. secondary bacterial infection pulmonary viruses viral" exact="pneumonia" post="SARS-CoV-2 COVID-19 influenza SARS antibiotic resistance fig-count: table-count: equation-count:"/>
 <result pre="pneumoniae. secondary bacterial infection pulmonary viruses viral pneumonia SARS-CoV-2 COVID-19" exact="influenza" post="SARS antibiotic resistance fig-count: table-count: equation-count: ref-count: page-count: word-count:"/>
 <result pre="result in respiratory tract infections. During the emergency of a" exact="viral disease," post="attention is initially focussed on clinical management of the"/>
 <result pre="(11, 12); infection with respiratory syncytial virus (RSV), rhinovirus and" exact="influenza" post="virus (all of which damage the mucosal layer), lead"/>
 <result pre="of SARS-CoV-2 infection typically include symptoms of mild fever and" exact="shortness" post="of breath (25). As the virus replicates in the"/>
 <result pre="pneumonia. In almost all severe cases, SARS-CoV-2 infection results in" exact="pneumonia" post="and the inflamed fluid-filled alveolar tissue now is an"/>
 <result pre="and challenges faced in treating SARS-CoV-2 infected patients. Patients with" exact="pneumonia" post="caused by other respiratory viruses or SARS-CoV-2 pneumonia patients"/>
 <result pre="Patients with pneumonia caused by other respiratory viruses or SARS-CoV-2" exact="pneumonia" post="patients were often prophylactically treated with broad-spectrum antibiotics, in"/>
 <result pre="viral respiratory illness but can rapidly progress to a fatal" exact="viral pneumonia" post="mostly complicated by ARDS (acute respiratory distress syndrome) and"/>
 <result pre="respiratory illness but can rapidly progress to a fatal viral" exact="pneumonia" post="mostly complicated by ARDS (acute respiratory distress syndrome) and"/>
 <result pre="and bilateral interstitial infiltrates in most cases, or ARDS. Nosocomial" exact="bacterial pneumonia" post="is however common among MERS patients with ventilator support."/>
 <result pre="bilateral interstitial infiltrates in most cases, or ARDS. Nosocomial bacterial" exact="pneumonia" post="is however common among MERS patients with ventilator support."/>
 <result pre="to cause seasonal flu every year and of the four" exact="influenza" post="types, type A and B are known to cause"/>
 <result pre="and B are known to cause seasonal epidemics (60). The" exact="influenza" post="A (H1N1) outbreak in 2009 had even developed into"/>
 <result pre="Secondary bacterial infections are one of the leading causes for" exact="influenza" post="associated deaths (62). According to the Center for Disease"/>
 <result pre="for Disease Control and Prevention (CDC), during the 2009 H1N1" exact="influenza" post="pandemic between 29 and 55% of mortalities were due"/>
 <result pre="due to secondary bacterial infections (63). The lethal synergism between" exact="influenza" post="virus and Pneumococcus strains accounts for the majority of"/>
 <result pre="for the majority of diseases as well as mortality during" exact="influenza" post="epidemics (64). Here, we summarize case studies that are"/>
 <result pre="(64). Here, we summarize case studies that are related to" exact="influenza" post="viruses and secondary bacterial infections (Supplementary File). Details on"/>
 <result pre="of a total of 910 patients that were infected with" exact="influenza" post="were reported in eight case studies (65–72). Five studies"/>
 <result pre="data regarding secondary bacterial infections following COVID-19, SARS, MERS and" exact="influenza" post="is surprising. In addition, precise numbers of clinical cases"/>
 <result pre="ill with pulmonary viral diseases. Similar to epidemics caused by" exact="influenza" post="viruses, during the current SARS-CoV-2 pandemic, antibiotic-resistant bacterial infections"/>
 <result pre="additional data file. References References 1.BradleyBTBryanA. Emerging respiratory Infections: The" exact="infectious disease" post="pathology of SARS, MERS, pandemic influenza, and Legionella. Semin"/>
 <result pre="Pathol. (2019) 36:152–9. 10.1053/j.semdp.2019.04.00631054790 2.MorrisDEClearyDWClarkeSC. Secondary bacterial infections associated with" exact="influenza" post="pandemics. Front Microbiol. (2017) 8:1041. 10.3389/fmicb.2017.0104128690590 3.WangHAnthonyDSelemidisSVlahosRBozinovskiS. Resolving viral-induced"/>
 <result pre="induces degradation of antimicrobial peptides and secondary bacterial infection in" exact="chronic obstructive pulmonary disease." post="Am J Respir Crit Care Med. (2012) 186:1117–24. 10.1164/rccm.201205-0806OC23024024"/>
 <result pre="the role of viral, host, and secondary bacterial factors in" exact="influenza" post="pathogenesis. Am J Pathol. (2015) 185:1528–36. 10.1016/j.ajpath.2014.08.03025747532 7.MacIntyreCRChughtaiAABarnesMRiddaISealeHTomsRet al.."/>
 <result pre="J Pathol. (2015) 185:1528–36. 10.1016/j.ajpath.2014.08.03025747532 7.MacIntyreCRChughtaiAABarnesMRiddaISealeHTomsRet al.. The role of" exact="pneumonia" post="and secondary bacterial infection in fatal and serious outcomes"/>
 <result pre="secondary bacterial infection in fatal and serious outcomes of pandemic" exact="influenza" post="a (H1N1) pdm09. BMC Infect Dis. (2018) 18:637. 10.1186/s12879-018-3548-030526505"/>
 <result pre="bacterial infections. Cell Host Microbe. (2011) 9:496–507. 10.1016/j.chom.2011.05.00621669398 9.JamiesonAMYuSAnnicelliCHMedzhitovR. Article" exact="influenza" post="virus-induced glucocorticoids compromise innate host defense against a secondary"/>
 <result pre="10.2147/TCRM.S8778926345407 11.NyangachaRMOdongoDOyiekeFOchwotoMKorirRNgetichRKet al.. Secondary bacterial infections and antibiotic resistance among" exact="tungiasis" post="patients in Western, Kenya. PLoS Neglect Trop D. (2017)"/>
 <result pre="Dis Rep. (2007) 9:186–92. 10.1007/s11908-007-0030-317430699 14.HandelALonginiIMAntiaR. Intervention strategies for an" exact="influenza" post="pandemic taking into account secondary bacterial infections. Epidem. (2009)"/>
 <result pre="(2002) 51:808–12. 10.1099/0022-1317-51-10-80812435058 17.BrookI. Microbiology of secondary bacterial infection in" exact="scabies" post="lesions. J Clin Microbiol. (1995) 33:2139–40. 10.1128/JCM.33.8.2139-2140.19957559963 18.MaharPDWasiakJClelandHPaulEGinDWattersDAet al.."/>
 <result pre="Burn Care Res. (2014) 35:518–24. 10.1097/BCR.000000000000006224988228 19.SmithAMMcCullersJASecondary bacterial infections in" exact="influenza" post="virus infection pathogenesis in influenza pathogenesis and control. Curr"/>
 <result pre="10.1097/BCR.000000000000006224988228 19.SmithAMMcCullersJASecondary bacterial infections in influenza virus infection pathogenesis in" exact="influenza" post="pathogenesis and control. Curr Top Microbiol Immunol. (2014) 385:327–56."/>
 <result pre="10.1097/IM9.0000000000000018 23.DuRHLiangLRYangCQWangWCaoTZLiMet al.. Predictors of mortality for patients with COVID-19" exact="pneumonia" post="caused by SARS-CoV-2: a prospective cohort study. Eur Respir"/>
 <result pre="and clinical characteristics of 99 cases of 2019 novel coronavirus" exact="pneumonia" post="in Wuhan, China: a descriptive study. Lancet. (2020) 395:507–13."/>
 <result pre="Clinical course and outcomes of critically ill patients with SARS-CoV-2" exact="pneumonia" post="in Wuhan, China: a single-centered, retrospective, observational study. Lancet"/>
 <result pre="Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus–infected" exact="pneumonia" post="in Wuhan, China. JAMA. (2020) 323:1061–9. 10.1001/jama.2020.158532031570 29.HolshueMLDeBoltCLindquistSLofyKHWiesmanJBruceHet al.First"/>
 <result pre="Med. (2020) 3:1–3. 10.1007/s00134-020-06028-z 32.WuCChenXCaiYZhouXXuSHuangHet al.. Risk factors associated with" exact="acute respiratory distress syndrome" post="and death in patients with coronavirus disease 2019 pneumonia"/>
 <result pre="distress syndrome and death in patients with coronavirus disease 2019" exact="pneumonia" post="in Wuhan, China. JAMA Intern Med. (2020) 180:1–11. 10.1001/jamainternmed.2020.099432167524"/>
 <result pre="patients assessed for COVID-19 infection; experience from a UK regional" exact="infectious disease" post="unit. Influenza Other Respir Viruses. (2020) 14:374–9. 10.1111/irv.1273932223012 37.ChenTWuDChenHYanWYangDChenGet"/>
 <result pre="at: http://www.who.int/csr/sars/country/table2004_04_21/en/ 42.Available, online at: http://www.who.int/csr/don/archive/disease/severe_acute_respiratory_syndrome/en/index.html 43.GuJKortewegCPathology and pathogenesis of" exact="severe acute respiratory syndrome." post="Am J Pathol. (2007) 170:1136–47. 10.2353/ajpath.2007.06108817392154 44.ChengVCChanJFToKKYuenKY. Clinical management"/>
 <result pre="(2013) 100:407–19. 10.1016/j.antiviral.2013.08.01623994190 45.ChongPYChuiPLingAEFranksTJTaiDYLeoYSet al.. Analysis of deaths during the" exact="severe acute respiratory syndrome" post="(SARS) epidemic in Singapore: challenges in determining a SARS"/>
 <result pre="10.1043/1543-2165(2004)128&amp;lt;195:AODDTS&amp;gt;2.0.CO;214736283 46.SoLKLauACYamLYCheungTMPoonEYungRWet al.. Development of a standard treatment protocol for" exact="severe acute respiratory syndrome." post="Lancet. (2003) 361:1615–7. 10.1016/S0140-6736(03)13265-512747883 47.LeeNHuiDWuAChanPCameronPJoyntGMet al.. A major outbreak"/>
 <result pre="Lancet. (2003) 361:1615–7. 10.1016/S0140-6736(03)13265-512747883 47.LeeNHuiDWuAChanPCameronPJoyntGMet al.. A major outbreak of" exact="severe acute respiratory syndrome" post="in Hong Kong. N Engl J Med. (2003) 348:1986–94."/>
 <result pre="(2003) 348:1986–94. 10.1056/NEJMoa03068512682352 48.TsangKWHoPLOoiGCYeeWKWangTChan-YeungMet al.. A cluster of cases of" exact="severe acute respiratory syndrome" post="in Hong Kong. N Engl J Med. (2003) 348:1977–85."/>
 <result pre="al.. Description and clinical treatment of an early outbreak of" exact="severe acute respiratory syndrome" post="(SARS) in Guangzhou, PR China. J Med Microbiol. (2003)"/>
 <result pre="at: https://www.who.int/csr/don/24-february-2020-mers-saudi-arabia/en/ 53.CunhaCBOpalSMMiddle east respiratory syndrome (MERS) A new zoonotic" exact="viral pneumonia." post="Virulence. (2014) 5:650–4. 10.4161/viru.3207725089913 54.MemishZACottenMWatsonSJKellamPZumlaAAlhakeemRFet al.. Community case clusters"/>
 <result pre="62.McCullersJA. Effect of antiviral treatment on the outcome of secondary" exact="bacterial pneumonia" post="after influenza. J Infect Dis. (2004) 190:519–26. 10.1086/42152515243927 63.collab:"/>
 <result pre="Effect of antiviral treatment on the outcome of secondary bacterial" exact="pneumonia" post="after influenza. J Infect Dis. (2004) 190:519–26. 10.1086/42152515243927 63.collab:"/>
 <result pre="10, 2020). 64.McCullersJABartmessKC. Role of neuraminidase in lethal synergism between" exact="influenza" post="virus and Streptococcus pneumoniae. J Infect Dis. (2003) 187:1000–9."/>
 <result pre="clinical features among patients hospitalized in Wisconsin with 2009. H1N1" exact="influenza" post="A virus infections, April to August. 2009. Wisconsin Med"/>
 <result pre="al.. Clinical features of the hospitalized patients with 2009 pandemic" exact="influenza" post="A (H1N1) in Santa Fe, Argentina. Influenza Other Respir"/>
 <result pre="68.Abelenda-AlonsoGRombautsAGudiolCMeijeYOrtegaLClementeMet al.. Influenza and bacterial coinfection in adults with community-acquired" exact="pneumonia" post="admitted to conventional wards: risk factors, clinical features, and"/>
 <result pre="(2020) 7:ofaa066. 10.1093/ofid/ofaa06632206675 69.HughesJMWilsonMEHughesJMWilsonMELeeEHWuCet al.Fatalities associated with the 2009. H1N1" exact="influenza" post="A virus in New York city. Clin Infect Dis."/>
 <result pre="Clin Infect Dis. (2010) 50:1498–504. 10.1086/65244620420514 70.ShiehWJBlauDMDenisonAMDeLeon-CarnesMAdemPBhatnagarJet al.. 2009 pandemic" exact="influenza" post="A (H1N1): pathology and pathogenesis of 100 fatal cases"/>
 <result pre="25:1–3. 10.1038/modpathol.2011.18021874012 72.Perez-PadillaRDe La Rosa-ZamboniDPonce de LeonSHernandezMQuiñones-FalconiFBautistaEet al.. Pneumonia and" exact="respiratory failure" post="from swine-origin influenza A (H1N1) in Mexico. N Engl"/>
 <result pre="Rosa-ZamboniDPonce de LeonSHernandezMQuiñones-FalconiFBautistaEet al.. Pneumonia and respiratory failure from swine-origin" exact="influenza" post="A (H1N1) in Mexico. N Engl J Med. (2009)"/>
</results>
